Research: healthcare AI startups have raised $4.3B across 576 deals since 2013, topping all other industries in AI deal activity
Context & Ripple Effects
By late 2017, the ten largest US tech companies were already involved in $2.7B worth of healthcare equity deals, up from $277M five years earlier — so CB Insights' finding that healthcare tops all industries in AI deal activity extends an existing land-grab rather than opening a new one. The same firm had just counted 141% YoY growth in overall AI investment to $15.2B in 2017, meaning healthcare's lead came at the peak of a sector-wide funding surge.
What makes the deal-count lead notable is durability: subsequent coverage shows the vertical kept absorbing capital through very different market conditions, from the record $20B quarter for AI startups in mid-2021 to the current phase where a handful of revenue-generating leaders capture most of the value.
First-order effects
- Healthcare founders and their investors now compete in the most crowded AI deal environment of any industry — 576 deals since 2013 means more funded competitors per niche and faster differentiation pressure on clinical products.
- Big tech's healthcare M&A and equity activity gives strategic acquirers an established pipeline into these startups, shaping exit paths beyond traditional health-system buyers.
Second-order effects
- Capital concentrates into proven subcategories: healthcare chatbot startups alone went on to raise $800M+ across 14 known companies, led by Babylon Health, showing how the broad deal activity funnels into specific clinical workflows.
- Documentation and administrative AI became the next magnet — medical note-taking app funding doubled to $800M in 2024 as Microsoft and others entered, pulling the battleground from diagnosis toward workflow software where distribution matters more than model quality.
Third-order effects
- If the pattern holds, healthcare shifts from being the widest AI deal funnel to a consolidation story: early breadth gives way to fewer, larger bets on applications with real revenue, mirroring the broader AI market where a small set of leaders captures most annualized value.
- Regulators and payers face a structural question as AI moves from experimental pilots to embedded clinical infrastructure — the volume of funded vendors makes governance and reimbursement rules, not technology, the sector's binding constraint.
The trend: Healthcare has been the most consistently funded vertical in AI since 2013, and its capital is migrating from broad early-stage deal counts toward concentrated bets on revenue-proven clinical applications.